Amylyx Pharmaceuticals (AMLX)
(Real Time Quote from BATS)
$8.12 USD
-0.06 (-0.73%)
Updated Aug 6, 2025 12:04 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Fundamental Charts
About Market Cap
As of the previous market close, Amylyx Pharmaceuticals, Inc. has a market cap of $729.17M, which represents its share price of $8.18 multiplied by its outstanding shares number of 89.14M. As a small-cap company, AMLX's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
AMLX 8.12 -0.06(-0.73%)
Will AMLX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AMLX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AMLX
Wall Street Analysts See a 105.22% Upside in Amylyx Pharmaceuticals (AMLX): Can the Stock Really Move This High?
PSTV Stock Skyrockets on FDA's Orphan Drug Tag for Cancer Therapy
AMLX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amylyx Pharmaceuticals (AMLX) Upgraded to Buy: What Does It Mean for the Stock?
Madrigal (MDGL) Reports Q2 Loss, Tops Revenue Estimates
FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates
Other News for AMLX
Vanguard Group Inc's Strategic Acquisition in Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025 | AMLX ...
BlackRock, Inc. Increases Stake in Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals: A High-Risk Pipeline With Strong Upside Potential
Amylyx (AMLX) Highlights Promising Avexitide Results at ENDO 2025 | AMLX Stock News